278 related articles for article (PubMed ID: 36959665)
41. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
42. A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.
Liu J; Lu Y; Dai Y; Shen Y; Zeng C; Liu X; Yu H; Deng J; Lu W
Front Genet; 2022; 13():939956. PubMed ID: 36105090
[No Abstract] [Full Text] [Related]
43. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
44. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
Zhou C; Li C; Zheng Y; Huang X
Front Oncol; 2022; 12():934076. PubMed ID: 36387247
[TBL] [Abstract][Full Text] [Related]
45. Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Cheng X; Zeng Z; Yang H; Chen Y; Liu Y; Zhou X; Zhang C; Wang G
BMC Cancer; 2023 Jan; 23(1):105. PubMed ID: 36717792
[TBL] [Abstract][Full Text] [Related]
46. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
47. Molecular Subtypes Based on Cuproptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Colorectal Cancer.
Huang H; Long Z; Xie Y; Qin P; Kuang L; Li X; Zhao Y; Zhang X; Yang L; Ma W; Xiao X; Liu Y; Sun X; Zhang M; Wang F; Hu D; Hu F
J Oncol; 2022; 2022():5034092. PubMed ID: 36276275
[TBL] [Abstract][Full Text] [Related]
48. Single-cell and genetic multi-omics analysis combined with experiments confirmed the signature and potential targets of cuproptosis in hepatocellular carcinoma.
Cao F; Qi Y; Wu W; Li X; Yang C
Front Cell Dev Biol; 2023; 11():1240390. PubMed ID: 37745297
[No Abstract] [Full Text] [Related]
49. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
[TBL] [Abstract][Full Text] [Related]
50. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
Wang F; Lin H; Su Q; Li C
World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
[TBL] [Abstract][Full Text] [Related]
51. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
52. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
53. Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma.
Chen S; Zhang S; Yuan Y; Wang Z; Li J; Li T; Zuo M; Feng W; Chen M; Liu Y
Front Pharmacol; 2022; 13():1016520. PubMed ID: 36267281
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
55. Comprehensiveness cuproptosis related genes study for prognosis and medication sensitiveness across cancers, and validation in prostate cancer.
Yang L; Tang Y; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
Sci Rep; 2024 Apr; 14(1):9570. PubMed ID: 38671021
[TBL] [Abstract][Full Text] [Related]
56. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
57. Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation.
Liu Z; Zhu F; Zhang P; Qian B; Liu W; Xiao Y; Chen N; He Q; Xiao J
Front Genet; 2022; 13():1074981. PubMed ID: 36506302
[No Abstract] [Full Text] [Related]
58. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
59. Cuproptosis patterns and tumor microenvironment in endometrial cancer.
Chen J; Wang G; Luo X; Zhang J; Zhang Y
Front Genet; 2022; 13():1001374. PubMed ID: 36226180
[TBL] [Abstract][Full Text] [Related]
60. Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis.
Shen Z; Cai J; Tao L; Zheng J; Ye Z; Liu Y; Pan H; Wang Y; Xu J; Liang X
Cancer Gene Ther; 2023 Dec; 30(12):1663-1678. PubMed ID: 37828105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]